Objective Key to reducing the spread of COVID-19 in the UK is increased use of the NHS Test and Trace (NHSTT) system. This study explored one of the main issues that determine whether people engage with NHSTT, how people understand symptoms that may indicate the presence of COVID-19 and that should trigger a request for a test. Methods In this qualitative study, a series of semi-structured telephone interviews were conducted with 40 people (21 members of the general population, 19 students). There was nearly an equal split between male and female participants in both populations. Data were collected between 30 November and 11 December 2020 and explored using thematic analysis. There was substantial similarity in responses for both populations so we combined our results and highlighted where differences were present. Results Participants generally had good knowledge of the main symptoms of COVID-19 (high temperature, new, persistent cough, anosmia) but had low confidence in their ability to differentiate them from symptoms of other illnesses. Attribution of symptoms to COVID-19 was most likely where the symptoms were severe, many symptoms were present, symptoms had lasted for some time and when perceived risk of exposure to infection was high due to previous contact with others. Participants felt encouraged to engage in testing where symptoms were present and had persisted for several days, though many had concerns about the safety of testing centres and the accuracy of test results. Students had mixed feelings about mass asymptomatic testing, seeing it as a way to access a more normal student experience, but also a potential waste of resources. Conclusions This study offers novel insights into how people attribute symptoms to COVID-19 and barriers and facilitators to engaging with testing. Participants had positive views of testing, but there is a need to improve not just recognition of each main symptom, but also understanding that even single, mild symptoms may necessitate a test rather than a wait and see approach, and to address concerns around test accuracy to increase testing uptake.
Objective: With the advent of a novel coronavirus in December 2019, several case studies have reported its adversity on cardiac cells. We conducted a systematic review that describes the symptomatology, prognosis, and clinical findings of patients with COVID-19-related myocarditis. Methods: Search engines including PubMed, Google Scholar, Cochrane Central, and Web of Science were queried for SARS-CoV-2 or COVID 19 and myocarditis. PRISMA guidelines were employed, and peer-reviewed journals in English related to COVID-19 were included. Results: This systematic review included 22 studies and 37 patients. Eight patients (36%) were confirmed myocarditis, while the rest were possible myocarditis. Most patients had elevated cardiac biomarkers, including troponin, CRP, CK, CK-MB, and NT-pro BNP. Electrocardiogram results noted tachycardia (47%), left ventricular hypertrophy (50%), ST-segment alterations (41%), and T wave inversion (18%). Echocardiography presented reduced LVEF (77%), left ventricle abnormalities (34%), right ventricle aberrations (12%), and pericardial effusion (71%). Further, CMR showed reduced myocardial edema (75%), non-ischemic patterns (50%), and hypokinesis (26%). The mortality was significant at 25%. Conclusions: Mortality associated with COVID-19 myocarditis appears significant but underestimated. Further studies are warranted to evaluate and quantify patients actual prognosis and outcomes with COVID-19 myocarditis.
Objective: To assess the COVID19 incidence per economic activity during the Autumn wave 2020 in Belgium. Methods: The 14-day incidence of confirmed COVID19 cases per NACEBEL code is described in the periods immediately preceding the Belgian more strict measures of October 19, 2020, and is evaluated longitudinally by a GaussianGaussian modelling twostage approach. Additionally, the number of high risk contacts in working segments and regions is described. Results: The peak of COVID19 14day incidence in most NACEBEL sectors is reached in the period October 20 November 2, 2020 and was considerably higher than average in human health activities, residential care activities, fitness facilities, human resource provision, hairdressing and other beauty treatment and some public service activities. Human health activities, residential care activities, food and beverage service activities, hotels, arts, food retail activities, and human resources provision have high pre-lockdown incidences. The frequency of index cases that report more than two high risk contacts is increasing over time in all sectors. Conclusion: Despite the restrictive protocols present in many sectors before the Autumn wave, employees in activities where close contact with others is high, show increased risk of COVID19 infection. Especially sports activities are among the highest risk activities. Finally, the increasing amount of high risk contacts by COVID19 confirmed cases is compatible with the decreasing motivation over time to adhere to the measures.
Background The city of Melbourne, Australia experienced two waves of the COVID-19 epidemic peaking in March and July 2020. During the second wave, a series of control measure were progressively introduced that initially slowed the growth of the epidemic then resulted in decreasing cases until there was no detectable local transmission. Methods To determine the relative efficacy of the progressively introduced intervention measures, we modelled this second wave as a series of exponential growth and decay curves. We used a linear regression of the log of daily cases vs time, using a four-segment linear spline model corresponding to implementation of the three successive major public health measures. The primary model used all reported cases between 14 June and 15 September then compared the projection of the model with observed cases predict future case trajectory up until the 31 October to assess the use of exponential models in projecting the future course and planning future interventions. The main outcome measures were the exponential daily growth constants, analysis of residuals and estimates of the 95% confidence intervals for the expected case distributions, comparison of predicted daily cases. Results: The exponential growth/decay constants in the primary analysis were: 0.122 (s.e. 0.004), 0.035 (s.e. 0.005), -0.037 (s.e. 0.011 ), and -0.069 (s.e. 0.003) for the initial growth rate, Stage 3, stage 3 + compulsory masks and Stage 4, respectively. Extrapolation of the regression model from the 14 September to the 31 October matched the decline in observed cases over this period. Conclusions: The four-segment exponential model provided an excellent fit of the observed reported case data and predicted the day-to-day range of expected cases. The extrapolated regression accurately predicted the decline leading to epidemic control in Melbourne.
Introduction: The COVID-19 pandemic was first reported in West Africa on 27 February 2020 in Nigeria. It subsequently spread to other countries in the region. The objective of this study is to analyze the epidemiological profile of COVID-19 in West Africa from the first reported case to 31 January 2021. Method: We publicly used available data from reliable sources and from the COVID-19R package. We used epidemic curves to describe the trends in the daily evolution of confirmed cases and deaths of COVID-19 in West Africa and specifically in the five countries. The reproduction rate and evolution rates were calculated from these trends. Results: As of 31 January 2021, West Africa had 342,938 confirmed cases of COVID-19 with 4,496 deaths. Nigeria had 131,242 cases with 1,586 deaths. Senegal had 26,523 cases with 628 deaths. The case-fatality rate in Mali was 4.08% and the attack rate in Cape Verde was 2587 cases per 100,000 inhabitants. In Nigeria, Senegal, Mauritania and Mali, the epidemic curves supported by the evolution rates showed an increase in confirmed cases and deaths of COVID-19 during December 2020 and January 2021 compared to the last two months. The effective reproduction rates (Re) inferred a slowdown in virus transmission (Re < 1) in these countries except for Senegal. Conclusion: The results showed that COVID-19 was still circulating in some West African countries in late 2020 and early 2021. By improving the health system and with context-specific public health interventions and vaccination, these countries should effectively control COVID-19. Keywords: Epidemiology, COVID-19, West Africa, Countries
Objective: To investigate the possible impact of Pfizer-BioNTech9s mRNA BNT162b2 COVID-19 vaccine on women9s fertility. Methods: A retrospective single-center study examining women9s IVF treatment parameters and pregnancies before and after their vaccination between February and May 2021. Each woman served as a self-control before and after vaccination. Additionally, in order to neutralize the effect of the sperm on fertilization, only Intracytoplasmic Sperm Injection (ICSI) patients who were currently being treated with an ICSI cycle and had an earlier ICSI cycle available were included in the study. The study outcomes compared between the PRE and POST vaccination groups and consisted of: the IVF cycle outcomes, including the number of oocytes retrieved; the number of matured oocytes; the fertilization rate; and the number and quality of embryos at day 3. Clinical pregnancy was based on the first hCG value reported if the data were available for both cycles. Results: A final total of 47 women were eligible for inclusion with a mean interval of 362 +/- 368 days between the two ovum pick ups. The characteristics of their ICSI cycles before and after the vaccination were similar for all the parameters. Additionally, the number and percentage of clinical pregnancies did not significantly differ between the PRE and POST vaccination groups (n=15). Conclusion: This study is the first to evaluate the impact of the BNT162b2 vaccine on women9s fertility. From our findings, the vaccine appears to have no impact on women9s fertility. This study is the first step in abolishing the misinformation derived from unreliable sources and reassuring patients in order to improve compliance and promote COVID-19 eradication.
The first confirmed case of COVID-19 in Quebec, Canada, occurred at Verdun Hospital on February 25, 2020. A month later, a localized outbreak was observed at this hospital. We performed tiled amplicon whole genome nanopore sequencing on nasopharyngeal swabs from all SARS-CoV-2 positive samples from 31 March to 17 April 2020 in 2 local hospitals to assess the viral diversity of the outbreak. We report 264 viral genomes from 242 individuals (both staff and patients) with associated clinical features and outcomes, as well as longitudinal samples, technical replicates and the first publicly disseminated SARS-CoV-2 genomes in Quebec. Viral lineage assessment identified multiple subclades in both hospitals, with a predominant subclade in the Verdun outbreak, indicative of hospital-acquired transmission. Dimensionality reduction identified two subclades that evaded supervised lineage assignment methods, including Pangolin, and identified certain symptoms (headache, myalgia and sore throat) that are significantly associated with favorable patient outcomes. We also address certain limitations of standard SARS-CoV-2 bioinformatics procedures, notably when presented with multiple viral haplotypes.
Early waves of the SARS-CoV-2 pandemic were driven by importation events and subsequent policy responses. However, epidemic dynamics in 2021 are largely driven by the spread of more transmissible and/or immune-evading variants, which in turn are countered by vaccination programs. Here we describe updates to the methodology of Covasim (COVID-19 Agent-based Simulator) to account for immune trajectories over time, correlates of protection, co-circulation of different variants and the roll-out of multiple vaccines. We have extended recent work on neutralizing antibodies (NAbs) as a correlate of protection to account for protection against infection, symptomatic COVID-19, and severe disease using a joint estimation approach. We find that NAbs are strongly correlated with infection blocking and that natural infection provides stronger protection than vaccination for the same level of NAbs, though vaccines typically produce higher NAbs. We find only relatively weak correlations between NAbs and the probability of developing symptoms given a breakthrough infection, or the probability of severe disease given symptoms. A more refined understanding of breakthrough infections in individuals with natural and vaccine-derived immunity will have implications for timing of booster vaccines, the impact of emerging variants of concern on critical vaccination thresholds, and the need for ongoing non-pharmaceutical interventions.
The incidence of acute kidney injury (AKI) in hospitalized patients with coronavirus disease 2019 (COVID-19) is variable, being associated with worse outcomes. The objectives of the study were to evaluate the incidence, risk factors and impact of AKI in subjects hospitalized for COVID-19 in two third- level hospitals in Córdoba, Argentina. A retrospective cohort study was conducted. 448 adults who were consecutively hospitalized for COVID-19 between March and the end of October 2020 at Hospital Privado Universitario de Córdoba and Hospital Raúl Angel Ferreyra were included. The incidence of AKI was 19% (n=85). 50.6% presented AKI stage 1 (n=43), 20% stage 2 (n=17) and 29.4% stage 3 (n=25, of which 18 required renal replacement therapy). In the multivariate analysis, the variables that were independently associated with AKI were: age (adjusted Odd ratio -aOR- =1.30, 95%CI=1.04-1.63, p=0.022), history of chronic kidney disease (aOR=9.92, 95%CI=4.52-21.77, p<0.001), blood neutrophil count at admission (aOR=1.09, 95%CI=1.01-1.18, p=0.037) and requirement for mechanical ventilation (MV) (aOR=6.69, 95%CI=2.24-19.9, p=0.001). AKI was associated with longer hospitalization, greater admission and length of stay in the intensive care unit, a positive association with bacterial superinfection, sepsis, respiratory distress syndrome, MV requirement and mortality (mortality with AKI=47.1% vs without AKI=12.4%, p<0.001). AKI was independently associated with higher mortality (aOR=3.32, 95%CI=1.6-6.9, p=0.001). In conclusion, the incidence of AKI in adults hospitalized for COVID-19 was 19% and had a clear impact on morbidity and mortality. Local predisposing factors for AKI were identified.
In recent years, the usage of digital polymerase chain reaction (dPCR) for various clinical applications has increased exponentially. Considering the growing demand for improved dPCR technology, the Clarity Plus™ dPCR system which features enhanced multiplexing capability and a wider dynamic range for nucleic acid analysis was recently launched. In this study, a dPCR assay optimized for use on Clarity Plus™ was evaluated for the absolute quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent responsible for the global coronavirus disease 2019 (COVID-19) outbreak. The assay demonstrated good inter- and intra- assay precision, accuracy, as well as excellent linearity across a range of over 6 orders of magnitude for target gene quantification. In addition, comparison of the assay on both dPCR and qPCR platforms revealed that dPCR exhibited a slightly higher sensitivity compared to its qPCR counterpart when quantifying SARS-CoV-2 at a lower concentration. Overall, the results showed that the dPCR assay is a reliable and effective approach for the absolute quantification of SARS-CoV-2 and can potentially be adopted as a molecular tool in applications such as detecting low viral loads in patients as well as in wastewater surveillance of COVID-19.
Background: Wastewater-based epidemiology has been used for monitoring human activities and waterborne pathogens. Although wastewaters can also be used for tracking SARS-CoV-2 at the population level, the reliability of this approach remains to be established, especially for early warning of outbreaks. Methods: We collected 377 samples from different treatment plants processing wastewaters of >1 million inhabitants in Valencia, Spain, between April 2020 and March 2021. Samples were cleaned, concentrated, and subjected to RT-qPCR to determine SARS-CoV-2 concentrations. These data were compared with cumulative disease notification rates over 7 and 14 day periods. Results: We amplified SARS-CoV-2 RNA in 75% of the RT-qPCRs, with an estimated detection limit of 100 viral genome copies per liter (gc/L). SARS-CoV-2 RNA concentration correlated strongly with disease notification rates over 14-day periods (Pearson r = 0.962, P < 0.001). A concentration >1000 gc/L showed >95% sensitivity and specificity as an indicator of more than 25 new cases per 100,000 inhabitants. Albeit with slightly higher uncertainty, these figures were reproduced using a 7-day period. Time series were similar for wastewaters data and declared cases, but wastewater RNA concentrations exhibited transient peaks that were not observed in declared cases and preceded major outbreaks by several weeks. Interpretation: Wastewater analysis provides a reliable tool for monitoring COVID-19, particularly at low incidence values, and is not biased by asymptomatic cases. Moreover, this approach might reveal previously unrecognized features of COVID-19 transmission.
Background. We set out in this paper to compare Covid-19 results by country to better understand the factors leading to the differing results found internationally. Methods. We used publicly available large datasets to explore differences by the country for Covid-19 mortality statistics. We continuously challenged our projections with reality and numbers from countries around the world, allowing us to refine our models and better understand the progression of the epidemic. All our predictions and findings were discussed and validated from a clinical viewpoint. Results. While no lockdown resulted in higher mortality, the difference between strict lock-down and a lax lockdown was not terribly different and favored lax lockdown. Only one of the top 44 countries had long and strict restrictions. Strict restrictions were more common in the worst-performing countries in terms of Covid mortality. The United States had the largest economic growth coupled with the largest rate of mortality. Those who did well economically had lower mortality and less pressure on their population. Yet they had less mortality than average and less than their neighbors. Conclusions. Countries with the least restrictions fared best economically. Some of them fared well in terms of mortality, even better than neighboring countries with similar social structures and more severe restrictions. The mortality rates in the USA, however, appeared to suffer from very high obesity rates. Norway and the northern European countries have less strict restrictions from the rest of Europe and had lower mortality rates. COVID-19 mortality was associated with vitamin D status.
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress - Condition: Covid19
Interventions: Biological: COVI-MSC; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) - Condition: Covid19
Interventions: Biological: COVI-DROPS; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) - Condition: Covid19
Interventions: Biological: COVI-DROPS; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study - Condition: COVID-19 Pneumonia
Intervention: Radiation: Low dose radiotherapy
Sponsor: Mahatma Gandhi Institute of Medical Sciences
Not yet recruiting
Using Text Messages to Improve COVID-19 Vaccination Uptake - Condition: Covid19
Intervention: Behavioral: Text message content
Sponsors: Imperial College Healthcare NHS Trust; Central London CCG; Imperial College Health Partners; Institute for Global Health Innovations; The Behavioural Insights Team
Not yet recruiting
Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC) - Condition: Covid19
Interventions: Drug: Ivermectin; Other: Placebo
Sponsor: Ministry of Public Health, Argentina
Recruiting
Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity - Condition: COVID-19
Interventions: Biological: mRNA-1273 SARS-CoV-2 vaccine; Biological: BNT162b2; Biological: ChAdOx1-S [recombinant]; Other: 0, 28 day schedule; Other: 0, 112 day schedule
Sponsors: Canadian Immunization Research Network; Canadian Center for Vaccinology; BC Children’s Hospital Research Institute; Children’s Hospital Research Institute of Manitoba; CHU de Quebec-Universite Laval; Ottawa Hospital Research Institute; Northern Alberta Clinical Trials + Research Centre; Ontario Agency for Health Protection and Promotion; University of Toronto; Massachusetts General Hospital
Not yet recruiting
CISCO-21 Prevent and Treat Long COVID-19. - Condition: Covid19
Intervention: Other: Resistance Exercise
Sponsors: NHS Greater Glasgow and Clyde; University of Glasgow; Chief Scientist Office of the Scottish Government
Not yet recruiting
Amantadine for COVID-19 - Condition: Covid19
Interventions: Drug: Amantadine; Drug: Lactose monohydrate
Sponsors: Copenhagen University Hospital, Hvidovre; University of Copenhagen
Not yet recruiting
Leronlimab in Moderatelly Ill Patients With COVID-19 Pneumonia - Condition: COVID-19 Pneumonia
Interventions: Drug: Leronlimab; Drug: Placebo
Sponsors: Hospital Israelita Albert Einstein; CytoDyn, Inc.
Not yet recruiting
Leronlimab in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation - Condition: COVID-19 Pneumonia
Interventions: Drug: Leronlimab; Drug: Placebo
Sponsors: Hospital Israelita Albert Einstein; CytoDyn, Inc.
Not yet recruiting
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients - Condition: COVID-19 Pneumonia
Intervention: Biological: Mesenchymal Stem Cells Transplantation
Sponsors: SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi; Istinye University; Liv Hospital (Ulus)
Completed
3R Rehabilitation Management of COVID-19 Survivors - Condition: Covid19
Interventions: Other: Cardiopulmonary exercise (centre-based); Other: Cardiopulmonary exercise (online-based)
Sponsors: The Hong Kong Polytechnic University; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Queen Elizabeth Hospital, Hong Kong; Princess Margaret Hospital, Hong Kong; Tuen Mun Hospital Hong Kong
Recruiting
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test - Condition: Covid19
Interventions: Device: Rapid antigen testing and offsite PCR testing; Device: Rapid antigen testing and onsite PCR testing
Sponsor: University of California, Los Angeles
Completed
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease - Condition: Covid19
Interventions: Other: Standard of Care; Biological: SARS-CoV2-CTLS
Sponsors: New York Medical College; Children’s Hospital of Philadelphia; Medical College of Wisconsin; Nationwide Children’s Hospital
Not yet recruiting
Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications - In view of many European countries and the USA leading to the second wave of COVID-19 pandemic, winter season, the evolution of new mutations in the spike protein, and no registered drugs and vaccines for COVID-19 treatment, the discovery of effective and novel therapeutic agents is urgently required. The degrees and frequencies of COVID-19 clinical complications are related to uncontrolled immune responses, secondary bacterial infections, diabetes, cardiovascular disease, hypertension, and…
Poly-L-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses - The C-type lectin receptor DC-SIGN mediates interactions with envelope glycoproteins of many viruses such as SARS-CoV-2, ebola, and HIV and contributes to virus internalization and dissemination. In the context of the recent SARS-CoV-2 pandemic, involvement of DC-SIGN has been linked to severe cases of COVID-19. Inhibition of the interaction between DC-SIGN and viral glycoproteins has the potential to generate broad spectrum antiviral agents. Here, we demonstrate that mannose-functionalized…
Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca(2+) -dependent membrane fusion - The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapeutics against the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and also against other pathogenic coronaviruses. In this study, we reported a kind of bisbenzylisoquinoline alkaloid, neferine, as pan-coronavirus entry inhibitor. Neferine effectively protected HEK293/hACE2 and HuH7 cell lines from infection by different coronaviruses pseudovirus…
Histone deficiency and accelerated replication stress in T cell aging - With increasing age, individuals are more vulnerable to viral infections such as with influenza or the SARS-CoV-2 virus. One age-associated defect in human T cells is the reduced expression of miR-181a. miR-181ab1 deficiency in peripheral murine T cells causes delayed viral clearance after infection, resembling human immune aging. Here we show that naive T cells from older individuals as well as miR-181ab1-deficient murine T cells develop excessive replication stress after activation, due to…
Molecular modeling of potent novel sulfonamide derivatives as non-peptide small molecule anti-COVID 19 agents - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for the COVID-19. The Sulfonamides groups have been widely introduced in several drugs, especially for their antibacterial activities and generally prescribed for respiratory infections. On the other hand, imidazole groups have the multipotency to act as drugs, including antiviral activity. We have used a structure-based drug design approach to design some imidazole derivatives of sulfonamide, which can…
Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2 - Airborne pathogens pose high risks in terms of both contraction and transmission within the respiratory pathways, particularly the nasal region. However, there is little in the way of adequate intervention that can protect an individual or prevent further spread. This study reports on a nasal formulation with the capacity to combat such challenges, focusing on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Formulation of a polysaccharide-based spray, known for its mucoadhesive…
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2 - No abstract
Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV - CONCLUSIONS: This study is the first to reveal quercetin as a pharmacological drug for COVID-19 and DENGUE co-infection. COVID-19 and DENGUE co-infection remain a potential threat to the world’s public health system. Therefore, we need innovative thinking to provide admissible evidence for quercetin as a potential molecule drug for the treatment of COVID-19 and DENGUE, but the findings have not been verified in actual patients, so further clinical drug trials are needed.
TLR7 Ligation Inhibits TLR8 Responsiveness in IL-27-Primed Human THP-1 Monocytes and Macrophages - Regulation of proinflammatory cytokine expression is critical in the face of single-stranded RNA (ssRNA) virus infections. Many viruses, including coronavirus and influenza virus, wreak havoc on the control of cytokine expression, leading to the formation of detrimental cytokine storms. Understanding the regulation and interplay between inflammatory cytokines is critical to the identification of targets involved in controlling the induction of cytokine expression. In this study, we focused on…
Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG - Hydroxychloroquine (HCQ) was noted to produce severe cardiac arrhythmia, an adverse effect as its use against severe acute respiratory syndrome caused by coronavirus 2 (SAES-CoV-2). HCQ is an antimalarial drug with quinoline structure. Some other quinoline compounds, such as fluoroquinolone antibiotics (FQs), also lead to arrhythmias characterized by QT prolongation. QT prolongation is usually related to the human ether-a-go-go-related gene (hERG) potassium channel inhibitory activity of most…
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants - The ongoing pandemic of COVID-19, caused by SARS-CoV-2, has severely impacted the global public health and socio-economic stability, calling for effective vaccines and therapeutics. In this study, we continued our efforts to develop more efficient SARS-CoV-2 fusion inhibitors and achieved significant findings. First, we found that the membrane-proximal external region (MPER) sequence of SARS-CoV-2 spike fusion protein plays a critical role in viral infectivity and can serve as an ideal template…
Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death - Most COVID-19 victims are old and die from unrelated causes. Here we present twelve complete autopsies, including two rapid autopsies of young patients where the cause of death was COVID-19 ARDS. The main virus induced pathology was in the lung parenchyma and not in the airways. Most coagulation events occurred in the intra-alveolar and not in the intra-vascular space and the few thrombi were mainly composed of aggregated thrombocytes. The dominant inflammatory response was the massive…
Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), which causes coronavirus disease-19 (COVID-19) has caused more than 2 million deaths around the globe. The high transmissibility rate of the disease is related to the strong interaction between the virus spike receptor-binding domain (RBD) and the human angiotensin-converting enzyme 2 (ACE2) as documented in several reports. In this study, using state-of-the-art computational methods, natural products were screened…
Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19 - Severe cases of coronavirus disease 2019 (COVID-19), caused by infection with SARS-CoV-2, are characterized by a hyperinflammatory immune response that leads to numerous complications. Production of proinflammatory neutrophil extracellular traps (NETs) has been suggested to be a key factor in inducing a hyperinflammatory signaling cascade, allegedly causing both pulmonary tissue damage and peripheral inflammation. Accordingly, therapeutic blockage of neutrophil activation and NETosis, the cell…
The First Insight Into the Supramolecular System of D,L-α-Difluoromethylornithine: A New Antiviral Perspective - Targeting the polyamine biosynthetic pathway by inhibiting ornithine decarboxylase (ODC) is a powerful approach in the fight against diverse viruses, including SARS-CoV-2. Difluoromethylornithine (DFMO, eflornithine) is the best-known inhibitor of ODC and a broad-spectrum, unique therapeutical agent. Nevertheless, its pharmacokinetic profile is not perfect, especially when large doses are required in antiviral treatment. This article presents a holistic study focusing on the molecular and…
COST EFFECTIVE PORTABLE OXYGEN CONCENTRATOR FOR COVID-19 - - link
METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) - - link
IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR - - link
DEEP LEARNING BASED SYSTEM FOR DETECTION OF COVID-19 DISEASE OF PATIENT AT INFECTION RISK - The present invention relates to Deep learning based system for detection of covid-19 disease of patient at infection risk. The objective of the present invention is to solve the problems in the prior art related to technologies of detection of covid-19 disease using CT scan image processing. - link
A COMPREHENSIVE DISINFECTION SYSTEM DURING PANDEMIC FOR PERSONAL ITEMS AND PROTECTIVE EQUIPMENT (PPE) TO SAFEGUARD PEOPLE - The current Covid-19 pandemic has led to an enormous demand for gadgets / objects for personal protection. To prevent the spread of virus, it is important to disinfect commonly touched objects. One of the ways suggested is to use a personal UV-C disinfecting box that is “efficient and effective in deactivating the COVID-19 virus. The present model has implemented the use of a UV transparent material (fused silica quartz glass tubes) as the medium of support for the objects to be disinfected to increase the effectiveness of disinfection without compromising the load bearing capacity. Aluminum foil, a UV reflecting material, was used as the inner lining of the box for effective utilization of the UVC light emitted by the UVC lamps. Care has been taken to prevent leakage of UVC radiation out of the system. COVID-19 virus can be inactivated in 5 minutes by UVC irradiation in this disinfection box - link
UBIQUITOUS COMPUTING SYSTEM FOR MENTAL HEALTH MONITORING OF PERSON DURING THE PANDEMIC OF COVID-19 - - link
一种预判重症新冠肺炎（COVID-19）的标志物及其产品和用途 - 本发明提供了一种预判重症疾病的标志物，所述的预判重症疾病的标志物为S100A12，序列为SEQ ID NO.1，所述的重症疾病为重症新冠肺炎、重症感染中的一种。S100A12基因作为标志物，在预判重症疾病时对全血中的S100A12基因的表达水平进行检测即可，无需对白细胞进行分离，简化检测流程。S100A12的表达水平可以指导感染类疾病包括新冠肺炎重症的预判，从而及早施治，降低病死率，具有很好的临床应用前景。 - link
INDICATING SYSTEM - A visual indicating system for use with a hospital bed, the hospital bed comprising a bed frame extending between a head end and a foot end of the bed frame, the visual indicating system comprising: an indicating member adapted to be coupled with the bed frame wherein the indicating member comprises an indicia for indicating one of a plurality of pre-determined health conditions.
FIGURE 1 - link
USE OF IMINOSUGAR COMPOUND IN PREPARATION OF ANTI-SARS-COV-2 VIRUS DRUG - - link
一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒 - 本发明公开了一种高灵敏SARS‑CoV‑2中和抗体的检测方法、检测试剂盒，属于生物医学检测技术领域，本发明试剂盒包括层析试纸、卡壳和样本稀释液，所述层析试纸包括底板、样品垫、结合垫、NC膜和吸水垫，所述NC膜上依次设置有捕获线、检测线和质控线，所述捕获线包被有ACE2蛋白，所述检测线包被有RBD蛋白，所述结合垫设置有RBD蛋白标记物；本发明采用阻断法加夹心法原理提高检测中和抗体的灵敏度，通过添加捕获线的方式，将靶向RBD的非中和抗体提前捕获，保证后续通过夹心法检测中和抗体的特异性。 - link